Comparative Pharmacology
Head-to-head clinical analysis: ILUMYA versus TREMFYA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ILUMYA versus TREMFYA.
ILUMYA vs TREMFYA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Humanized IgG1κ monoclonal antibody that selectively binds to the p19 subunit of interleukin-23 (IL-23), inhibiting its interaction with the IL-23 receptor, thereby blocking downstream signaling and production of pro-inflammatory cytokines such as IL-17 and IL-22.
Guselkumab is a human monoclonal antibody that selectively binds to the p19 subunit of interleukin-23 (IL-23) and inhibits its interaction with the IL-23 receptor, thereby blocking IL-23-mediated signaling and the downstream activation of Th17 cells and production of proinflammatory cytokines.
100 mg subcutaneously once every 12 weeks.
Subcutaneous injection: 100 mg at week 0, week 4, then every 8 weeks thereafter.
None Documented
None Documented
Approximately 22-24 days (range 18-27 days), supporting quarterly (every 12 weeks) subcutaneous dosing in plaque psoriasis.
Terminal elimination half-life approximately 23-31 days (mean ~27 days), supporting subcutaneous dosing every 8 weeks after initial loading.
Primarily eliminated via degradation into small peptides and amino acids; renal and biliary/fecal routes are negligible as intact molecule.
Primarily degraded into small peptides and amino acids via general protein catabolism; no significant renal or hepatic elimination. Fecal excretion of intact drug is negligible.
Category C
Category C
IL-23 Inhibitor
IL-23 Inhibitor